Matthew J. Everly

3.5k total citations · 1 hit paper
81 papers, 2.6k citations indexed

About

Matthew J. Everly is a scholar working on Transplantation, Surgery and Immunology. According to data from OpenAlex, Matthew J. Everly has authored 81 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Transplantation, 41 papers in Surgery and 21 papers in Immunology. Recurrent topics in Matthew J. Everly's work include Renal Transplantation Outcomes and Treatments (61 papers), Organ Transplantation Techniques and Outcomes (32 papers) and Transplantation: Methods and Outcomes (18 papers). Matthew J. Everly is often cited by papers focused on Renal Transplantation Outcomes and Treatments (61 papers), Organ Transplantation Techniques and Outcomes (32 papers) and Transplantation: Methods and Outcomes (18 papers). Matthew J. Everly collaborates with scholars based in United States, China and United Kingdom. Matthew J. Everly's co-authors include Paul I. Terasaki, Lorita M. Rebellato, Kimberly P. Briley, Carl E. Haisch, Paul Bolin, Scott A. Kendrick, William T. Kendrick, Robert C. Harland, Lan Zhu and Wen‐Jeng Lee and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Immunology and Hepatology.

In The Last Decade

Matthew J. Everly

80 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Incidence and Impact of De Novo Donor-Specific Alloantibody in Primary Renal Allografts

2013 292 citations Matthew J. Everly, Lorita M. Rebellato et al. Transplantation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthew J. Everly United States	29	1.9k	1.3k	643	525	284	81	2.6k
Marie‐Paule Emonds Belgium	26	1.2k 0.7×	1.0k 0.8×	461 0.7×	296 0.6×	333 1.2×	102	2.2k
Alice Peng United States	28	2.3k 1.2×	1.2k 0.9×	937 1.5×	741 1.4×	364 1.3×	62	3.1k
Alin Girnita United States	28	1.6k 0.8×	1.2k 0.9×	498 0.8×	274 0.5×	256 0.9×	59	2.1k
Gema Fernández‐Fresnedo Spain	27	1.2k 0.6×	743 0.6×	429 0.7×	637 1.2×	261 0.9×	116	2.3k
Milagros Samaniego United States	27	1.3k 0.7×	866 0.6×	309 0.5×	459 0.9×	262 0.9×	76	2.0k
Marko J.K. Mallat Netherlands	26	1.3k 0.7×	972 0.7×	307 0.5×	452 0.9×	187 0.7×	51	2.1k
H.-U. Meier-Kriesche United States	20	1.8k 0.9×	918 0.7×	301 0.5×	276 0.5×	390 1.4×	43	2.3k
Olivier Aubert France	24	1.8k 0.9×	1.1k 0.8×	457 0.7×	507 1.0×	277 1.0×	67	2.1k
Edmund Huang United States	28	1.2k 0.6×	798 0.6×	217 0.3×	347 0.7×	177 0.6×	85	2.0k
David A. Laskow United States	21	1.1k 0.6×	753 0.6×	265 0.4×	341 0.6×	142 0.5×	50	2.1k

Countries citing papers authored by Matthew J. Everly

Since Specialization

Citations

This map shows the geographic impact of Matthew J. Everly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew J. Everly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew J. Everly more than expected).

Fields of papers citing papers by Matthew J. Everly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew J. Everly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew J. Everly. The network helps show where Matthew J. Everly may publish in the future.

Co-authorship network of co-authors of Matthew J. Everly

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew J. Everly. A scholar is included among the top collaborators of Matthew J. Everly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew J. Everly. Matthew J. Everly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kawakita, Satoru, Jennifer L. Beaumont, Vadim Jucaud, & Matthew J. Everly. (2020). Personalized prediction of delayed graft function for recipients of deceased donor kidney transplants with machine learning. Scientific Reports. 10(1). 18409–18409. 29 indexed citations

Beaumont, Jennifer L., et al.. (2019). Trajectories of health-related quality of life among renal transplant patients associated with graft failure and symptom distress: Analysis of the BENEFIT and BENEFIT-EXT trials. American Journal of Transplantation. 20(6). 1650–1658. 15 indexed citations

Nakamura, Kojiro, Shoichi Kageyama, Takahiro Ito, et al.. (2019). Antibiotic pretreatment alleviates liver transplant damage in mice and humans. Journal of Clinical Investigation. 129(8). 3420–3434. 69 indexed citations

Jucaud, Vadim, Abraham Shaked, Michele Desmarais, et al.. (2018). Prevalence and Impact of De Novo Donor‐Specific Antibodies During a Multicenter Immunosuppression Withdrawal Trial in Adult Liver Transplant Recipients. Hepatology. 69(3). 1273–1286. 46 indexed citations

Stegall, Mark D., Matthew J. Everly, Roslyn B. Mannon, et al.. (2018). The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium’s position statement. American Journal of Transplantation. 19(3). 625–632. 12 indexed citations

Everly, Matthew J., Mustimbo Roberts, Robert Townsend, Robert A. Bray, & Howard M. Gebel. (2018). Comparison of de novo IgM and IgG anti-HLA DSAs between belatacept- and calcineurin-treated patients: An analysis of the BENEFIT and BENEFIT-EXT trial cohorts. American Journal of Transplantation. 18(9). 2305–2313. 28 indexed citations

Lachmann, Nils, Constanze Schönemann, Nadim El‐Awar, et al.. (2016). Dynamics and epitope specificity of anti-human leukocyte antibodies following renal allograft nephrectomy. Nephrology Dialysis Transplantation. 31(8). 1351–1359. 21 indexed citations

Cheng, Elaine, Matthew J. Everly, Hugo Kaneku, et al.. (2016). Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients. Transplantation. 101(4). 873–882. 47 indexed citations

Huang, Edmund, et al.. (2014). The UNOS Renal Transplant Registry: Review of the Last Decade.. PubMed. 1–12. 30 indexed citations

10.

Hoshino, Junichi, Matthew J. Everly, Hugo Kaneku, et al.. (2014). Impact of the Presence and Duration of Donor-Specific Antibodies on Renal Function. Transplantation Proceedings. 46(1). 75–80. 5 indexed citations

11.

Everly, Matthew J., Lorita M. Rebellato, Carl E. Haisch, et al.. (2014). Impact of IgM and IgG3 Anti-HLA Alloantibodies in Primary Renal Allograft Recipients. Transplantation. 97(5). 494–501. 58 indexed citations

12.

Everly, Matthew J., Lorita M. Rebellato, Carl E. Haisch, et al.. (2014). Changes in Successive Measures of De Novo Donor-Specific Anti–Human Leukocyte Antigen Antibodies Intensity and The Development of Allograft Dysfunction. Transplantation. 98(10). 1097–1104. 13 indexed citations

13.

Wu, Pingping, et al.. (2013). Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation. Clinical Biochemistry. 46(15). 1389–1393. 34 indexed citations

14.

Everly, Matthew J., Lorita M. Rebellato, Carl E. Haisch, et al.. (2013). Incidence and Impact of De Novo Donor-Specific Alloantibody in Primary Renal Allografts. Transplantation. 95(3). 410–417. 292 indexed citations breakdown →

15.

Everly, Matthew J. & Paul I. Terasaki. (2011). The state of therapy for removal of alloantibody producing plasma cells in transplantation. Seminars in Immunology. 24(2). 143–147. 16 indexed citations

16.

Patel, J., Matthew J. Everly, D. Chang, et al.. (2011). Reduction of alloantibodies via proteosome inhibition in cardiac transplantation. The Journal of Heart and Lung Transplantation. 30(12). 1320–1326. 108 indexed citations

17.

Trivedi, Hargovind L., Paul I. Terasaki, A Feroz, et al.. (2009). Abrogation of Anti-HLA Antibodies via Proteasome Inhibition. Transplantation. 87(10). 1555–1561. 129 indexed citations

18.

Everly, Matthew J. & Paul I. Terasaki. (2009). Monitoring and treating posttransplant human leukocyte antigen antibodies. Human Immunology. 70(8). 655–659. 27 indexed citations

19.

Everly, Matthew J., J Everly, Brian Susskind, et al.. (2008). Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection. Transplantation. 86(12). 1754–1761. 306 indexed citations

20.

Everly, Matthew J., Pamela C. Heaton, & Robert J. Cluxton. (2004). β-Blocker Underuse in Secondary Prevention of Myocardial Infarction. Annals of Pharmacotherapy. 38(2). 286–293. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact